Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
80005.590.2066%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Vanda Pharmaceuticals Inc

VNDANASDAQ
Trade with Public
Trade with Public
$5.43
0.091.69%
At close: Sep 4, 5:00 PM EST
$5.45
0.020.37%
After Hours: Sep 4, 4:57 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Vanda Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vanda Pharmaceuticals (VNDA).

Price Target Range — 9 Quarters

Analyst Consensus — 5 Analysts

4Buy
1Hold
Consensus RatingBuy# Analysts5Avg. Consensus PT$14Upside to Avg. PT+149.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 10, 2026B. Riley SecuritiesMadison El-SaadiPT CutBuy$17→$12
Aug 10, 2026HC Wainwright & Co.Raghuram SelvarajuPT CutBuy$21→$20
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
B. Riley Securities Reiterates Buy on Vanda Pharmaceuticals, Lowers Price Target to $12

B. Riley Securities analyst Madison El-Saadi reiterates Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $17 to $12.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $20

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $21 to $20.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $21

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $24 to $21.
Benzinga Newsdesk

This Equinix Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Top Wall Street analysts changed outlook on top names. See analyst ratings page for full view. EQIX stock initiated with Outperform rating.
Avi Kapoor

PRO
Truist Securities Initiates Coverage On Vanda Pharmaceuticals with Buy Rating, Announces Price Target of $18

Truist Securities analyst Les Sulewski initiates coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy rating and announces Price Target of $18.
Benzinga Newsdesk

Analyst Expectations For Vanda Pharmaceuticals's Future

Benzinga Insights

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved